Companies Dominating the Entropion Treatment Landscape
- Alembic Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- Bausch & Lomb Incorporated
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Sanofi-aventis Groupe
- Abbott Laboratories
- Merck & Co., Inc.
- Siemens Healthcare GmbH
- Pfizer Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of entropion treatment is assessed at USD 507.6 million.
The entropion treatment market size was over USD 456.57 million in 2024 and is projected to reach USD 1.07 billion by 2037, witnessing around 6.8% CAGR during the forecast period i.e., between 2025-2037. Increasing geriatric population, rising success of the entropion treatment, the growing popularity of contact lenses, and increasing cases of dry eye syndrome will drive the market growth.
North America industry is anticipated to hold largest revenue share by 2037, due to rising cases of entropion in older adults, and higher number of people suffering with dry eye issues.
The major players in the market are Eli Lilly and Company, Bausch & Lomb Incorporated, Sun Pharmaceutical Industries Ltd., Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., and Alembic Limited
